About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The big jobs numbers out this week came from this morning’s U.S. Bureau of Labor Statistics' (BLS) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for. A big upward revision for December accompanies this headline, from 216K originally reported to 333K today. These are far and away the strongest months for jobs gains in the past 12 months. The Unemployment Rate stayed at 3.7%, where it’s been for ...

营收情况 - AbbVie (ABBV) 2023年第四季度营收为143亿美元，同比下降5.4% [1] - 营收超出Zacks Consensus Estimate 1.78% [1] 每股收益 - 每股收益为2.79美元，较去年同期的3.60美元下降 [1] - 每股收益超出预期1.09% [1] 产品表现 - Humira在美国的净收入为27.4亿美元，较分析师平均预期的27亿美元高 [4] - Skyrizi在国际市场的净收入为2.89亿美元，同比增长67.1% [5] - Skyrizi在美国市场的净收入为21.1亿美元，同比增长50% [6] - Humira在国际市场的净收入为5.64亿美元，较分析师平均预期的4.83亿美元高 [7] 业务板块 - 眼科业务总净收入为5.85亿美元，较分析师平均预期的5.675亿美元高 [8] - 美容业务总净收入为13.7亿美元，较分析师平均预期的13.5亿美元高 [9] - 免疫学业务总净收入为69.5亿美元，较分析师平均预期的67.9亿美元高 [10] - 血液肿瘤学业务总净收入为15.1亿美元，较分析师平均预期的14.4亿美元高 [11] - 神经科学业务总净收入为20.9亿美元，同比增长22.5% [12] - 其他美容业务总净收入为3.19亿美元，较分析师平均预期的3.2625亿美元低 [13] - 其他神经科学业务总净收入为6600万美元，同比增长8.2% [14] - Rinvoq总净收入为12.6亿美元，较分析师平均预期的11.9亿美元高 [14]

Key PointsAbbVie's treatment for patent-cliff woes is working and has the company on track to return to growth soon. Humira continues to outperform, and the non-Humira portfolio is more robust than expected. The pipeline is robust and amplified by recently announced acquisitions expected to close this year. 5 stocks we like better than AbbVieAbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, an ...

The fourth-quarter earnings season is in full swing for the drug and biotech sector.  The performance of the large drugmakers that have reported so far has been rather lukewarm, with most posting mixed results.Higher tax rates due to changes in global tax regulations, concerns around the economy and inflation, regular pipeline setbacks and the slow ramp-up of newer drugs are some concerns of drug developers. Uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s ...

AbbVie第四季度业绩 - AbbVie第四季度每股收益为2.79美元，超过了Zacks Consensus Estimate的2.76美元[1] - AbbVie在过去四个季度中四次超过了市场预期的每股收益[2] - AbbVie第四季度营收为143亿美元，超过了Zacks Consensus Estimate的141亿美元[3] - AbbVie股价自年初以来上涨了约8.1%，表现优于标普500指数的涨幅[4]

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon.The American medical R&D powerhouse had some setbacks in the year, including disappointing profits from their drug Humira, which lost significant market share to generic knockoffs in both the US and abroad in 2023. Full year resultsCopy link to sectionThe company reported net revenues of $54.318 billion, 6.4 percent less YoY than 2022, and diluted EPS of $2.72 for the full year on a GAAP basis ...

AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported fourth-quarter net income of $822 million, or 46 cents per share, down sharply from $2.473 billion, or $1.38 per share, in the year-earlier period. Adjusted earnings per share of $2.79, which included an unfavorable impact of 15 cents a share related to acquired in-process research and development expenses, matched th ...

文章核心观点 - 公司2023年全年业绩表现出色,非Humira业务增长强劲,但受Humira专利到期影响整体收入下降[1][2] - 公司通过收购ImmunoGen和Cerevel Therapeutics进一步丰富了肿瘤和神经科学领域的管线[17][18] - 公司预计2024年业绩将受到收购事项的一定影响,但长期增长前景仍然良好,预计未来几年保持高个位数的复合年增长率[27][28] 业务板块总结 免疫学业务 - 免疫学业务收入下降9.6%,主要受Humira专利到期影响,但Skyrizi和Rinvoq收入大幅增长[3] - Humira全球收入下降32.2%,其中美国市场下降34.7%,国际市场下降14.3%[38] - Skyrizi全球收入增长50.3%,Rinvoq全球收入增长57.4%[38] 肿瘤业务 - 肿瘤业务收入下降10.1%,主要受Imbruvica收入下降21.3%的影响,Venclexta收入增长13.9%[38] 神经科学业务 - 神经科学业务收入增长18.2%,主要得益于Botox治疗剂、Vraylar和Ubrelvy等产品的强劲表现[9] - Botox治疗剂收入增长10.0%,Vraylar收入增长35.4%,Ubrelvy收入增长19.9%[38] 美学业务 - 美学业务收入下降0.8%,Botox美容和Juvederm收入分别增长2.6%和下降3.6%[38] 其他信息 - 公司2023年第四季度调整后每股收益为2.79美元,全年调整后每股收益为11.11美元[15][40] - 公司预计2024年调整后每股收益将为11.05-11.25美元,其中包括收购事项的0.32美元摊薄影响[27] - 公司预计未来几年保持高个位数的复合年增长率,并大幅提高了Skyrizi和Rinvoq以及Ubrelvy和Qulipta的长期销售预期[28][29][30]

生物技术行业发展趋势 - 生物技术行业预计在2023年至2030年间复合年增长率接近13%[1] 人工智能在生物技术领域的应用 - 人工智能在生物技术领域有重要应用[2] - CRISPR基因编辑技术不断发展，包括商业层面的新应用[2] AbbVie公司的销售情况 - AbbVie公司的销售主要受其明星药物Humira的影响[4] - 公司正在积极用新药替代Humira的销售下滑[4]